DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Zaleplon 10mg Capsules Under Fasting Conditions

Information source: Teva Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Zaleplon 10 mg Capsules (Drug); Sonata® 10 mg Capsules (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Teva Pharmaceuticals USA

Official(s) and/or principal investigator(s):
So Ran Hong, M.D., Principal Investigator, Affiliation: Novum Pharmaceutical Research Services

Summary

The objective of this study was to compare the relative bioavailability of Zaleplon 10 mg Capsules manufactured by TEVA Pharmaceuticals USA and Sonata® 10 mg Capsules manufactured by Wyeth Laboratories in healthy, non-smoking adults under fasting conditions.

Clinical Details

Official title: A Relative Bioavailability Study of Zaleplon 10mg Capsules Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

Cmax - Maximum Observed Concentration

AUC0-Inf - Area Under the Concentration-Time Curve From Time Zero to Infinity (Extrapolated)

AUC0-t - Area Under the Concentration-Time Curve From Time Zero to Time of Last Non-Zero Concentration (Per Participant)

Detailed description: Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- non-smokers

- at least 18 years of age

- BMI of 30 or less

Exclusion Criteria:

- Subjects with a significant recent history of chronic alcohol consumption (past 2

years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma (past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.

- Subjects whose clinical laboratory test values are outside the reference ranges may

be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.

- Subjects who have a history of allergic responses to the class of drug being tested

will be excluded from the study. Subjects with intolerance to alcohol or other CNS depressants should not participate in this study.

- Subjects who use tobacco in any form will not be eligible to participate in the

study. Three months abstinence is required.

- All subjects will have urine samples assayed for the presence of drugs of abuse as

part of the clinical laboratory screening procedures and at each dosing period check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.

- Subjects should not have donated blood and/or plasma for at least thirty (30) days

prior to the first dosing of the study.

- Subjects who have taken any investigational drug within thirty (30) days prior to the

first dosing of the study will not be allowed to participate.

- Female subjects who are pregnant, breast-feeding, or who are likely to become

pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e. g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate. Female subjects who have used hormonal oral contraceptives within 14 days of dosing or implanted or injected hormonal contraceptives within 180 days of dosing will not be allowed to participate.

- All female subjects will be screened for pregnancy at check-in each study period.

Subjects with positive or inconclusive results will be withdrawn from the study.

- Subjects who do not tolerate venipuncture will not be allowed to participate.

Locations and Contacts

Novum Pharmaceutical Research Services, Houston, Texas 77040, United States
Additional Information

Starting date: February 2004
Last updated: July 6, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017